Ionis Pharmaceuticals, Inc. (FRA:ISI)

Market Cap	10.55B +162.9%
Revenue (ttm)	803.76M +33.8%
Net Income	-324.83M
EPS	-2.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	9
Open	63.42
Previous Close	63.34
Day's Range	63.42 - 63.42
52-Week Range	25.40 - 72.60
Beta	n/a
RSI	47.41
Earnings Date	Apr 29, 2026

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 1,402
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ISI

Financial Performance

In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.

Financial numbers in USD